PatriciaMucciLorussoDO

Gastrointestinal Cancer

Professor of Medicine (Medical Oncology); Professor of Medicine; Associate Director of Innovative Medicine at Yale Cancer Center

Join to view full profile

Dr. Lorusso is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lorusso's full profile

Already have an account?

Office
55 Park Street
Yale Cancer Center
New Haven, CT 06519
Phone+1 203-785-4095
Is this information wrong?

Summary

Pat LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1985 - 1988
Michigan State University College of Osteopathic MedicineClass of 1981

Certifications & Licensure

CT State License 2014 - 2024
MI State License 1981 - 2015
AOA Board of Internal Medicine Hematology/Oncology
AOA Board of Internal Medicine Internal Medicine
AOA Board of Internal Medicine Oncology

Clinical Trials

Pyrazoloacridine in Treating Women With Metastatic Breast Cancer Start of enrollment: 1994 Feb 01
Completed
Phase 2
KRN5500 in Treating Patients With Metastatic Solid Tumors Start of enrollment: 1997 May 01
Completed
Phase 1
Fenretinide in Treating Patients With Solid Tumors Start of enrollment: 1998 May 01
Completed
Phase 1
XK469 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jan 01
Completed
Phase 1
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction Start of enrollment: 2004 Jul 01
Completed
Phase 1
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Completed
Phase 1
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors Start of enrollment: 2006 Feb 01
Completed
AFP464 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Jun 01
Terminated
Phase 1
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors Start of enrollment: 2005 Jan 01
Completed
Phase 1
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) Start of enrollment: 2007 Dec 14
Active, not recruiting
Phase 1
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 1
Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2009 May 01
Completed
Not Applicable
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
Suspended
Not Applicable
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2011 Mar 01
Terminated
Phase 1
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2010 Aug 06
Completed
Phase 2
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Study of DS-2248 in Participants With Advanced Solid Tumors Start of enrollment: 2011 Mar 29
Terminated
Phase 1
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2011 Mar 03
Completed
Phase 1
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
Active, not recruiting
Phase 1
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
Completed
Phase 1
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23
Terminated
Phase 1
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 19
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
Active, not recruiting
Phase 1
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
Active, not recruiting
Phase 1
Study of ASTX029 in Subjects With Advanced Solid Tumors Start of enrollment: 2018 May 10
Recruiting
Phase 1, Phase 2
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Start of enrollment: 2022 Nov 16
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors Start of enrollment: 2019 Jun 13
Active, not recruiting
Phase 1
Roles: Contact
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Roussos Torres, E., Ho, W., Danilova, L., Tandurella, J., Leatherman, J., Rafie, C., Wang, C., Brufsky, A., LoRusso, P., Chung, V., Yuan, Y., Downs, M., O'Connor, A., ...> ;Nature Cancer. 2024 Feb 14
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Narayan, A., Xu, Y., Wolfe, J., Vu, D., Trinh, T., Kantak, C., Ivy, S., Deng, Y., Patel, A., Hu, Y., Eder, J., LoRusso, P., Kim, J.> ;JCO Precision Oncology. 2024 Feb 1
3 citations
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis, G., Li, G., Guo, J., Yu, S., Fields, C., Lee, G., Zhang, D., Dragovich, P., Pillow, T., Wei, B., Sadowsky, J., Leipold, D., Wilson, T., Kamath, A., Mamounas, M....> ;Nature Communications. 2024 Jan 11
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Noboru Yamamoto, Iwona Lugowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Anthony Tolcher, Navid Hafez, Patricia LoRusso> ;Oncotargets and Therapy. 2024 Jan 1
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward Kim, Stacey Stein, ...> ;British Journal of Cancer. 2024 Feb 1
2 citations
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Elena Garralda, Do Youn Oh, Antoine Italiano, Philippe L Bedard, Jean-Pierre Delord, Emiliano Calvo, Patricia LoRusso, Zev Wainberg, Andres Cervantes, Alejo Rodriguez-...> ;Journal of Clinical Pharmacology. 2024 May 1
2 citations
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai, J., Alonso, G., Kim, S., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W., P...> ;Nature Medicine. 2024 Jan 1
8 citations
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Tae Won Kim, Philippe L Bedard, Patricia LoRusso, Michael S Gordon, Johanna Bendell, Do-Youn Oh, Myung-Ju Ahn, Elena Garralda, Sandra P D'Angelo, Jayesh Desai, F Steph...> ;JAMA Oncology. 2023 Nov 1
7 citations
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
Patricia LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M Gounder> ;Cancer Discovery. 2023 Aug 4
4 citations
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaoji...> ;The Oncologist. 2024 Jan 5
1 citations
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors.
Michael A Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, P...> ;Cancer Research Communications. 2023 Aug 1
1 citations
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.
Thomas J George, Tara L Lin, Tricia Adrales Bentz, Stefan Grant, Collette M Houston, Melissa A Nashawati, Bhanu Pappu, Helen Peck, Alex Zafirovski, Kimberly Kerstann, ...> ;JNCI Cancer Spectrum. 2023 Jul 3
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kort...> ;Cancer Research Communications. 2023 Jun 1
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph P Eder, Kurt A Schalper, Alice P Chen, Patricia LoRusso> ;Cancer Research Communications. 2023 Jun 1
13 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, John H Strickler, Sang-We Kim, Stephen Clarke, Thomas J George, Peter S Grimison, Mina...> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
1 citations
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrentand-mutant Glioma.
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pie...> ;Cancer Research Communications. 2023 Feb 1
16 citations
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Mrinal M Gounder, Todd M Bauer, Gary K Schwartz, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G Tirunagaru,...> ;Journal of Clinical Oncology. 2023 Mar 20
9 citations
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer.
Karan K Budhraja, Bradon R McDonald, Michelle D Stephens, Tania Contente-Cuomo, Havell Markus, Maria Farooq, Patricia F Favaro, Sydney Connor, Sara A Byron, Jan B Egan...> ;Science Translational Medicine. 2023 Jan 11
1 citations
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.
Patricia M LoRusso, Boris Freidlin> ;Journal of the National Cancer Institute. 2023 Feb 8
4 citations
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Timothy A Yap, Patricia M LoRusso, Deborah J Wong, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leun...> ;Clinical Cancer Research. 2023 Mar 1
14 citations
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W Kim, Rana R McKay, Marc R Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B Davis, Paul Monk, Leonard J Appleman, Primo N Lara Jr, Ulka N Vaishampayan, Jingsong ...> ;Journal of Clinical Oncology. 2023 Feb 1
7 citations
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Patricia LoRusso, Mark J Ratain, Toshihiko Doi, Drew W Rasco, Maja J A de Jonge, Victor Moreno, Benedito A Carneiro, Lot A Devriese, Adam Petrich, Dimple Modi, Susan M...> ;Investigational New Drugs. 2022 Aug 1
15 citations
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
16 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
28 citations
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M LoRusso, Guzman Alonso, ...> ;Cancer Discovery. 2022 May 2
Join now to see all

Press Mentions

TRIGR Therapeutics Announces Formation of Global Clinical & Scientific Advisory BoardMay 13th, 2019
Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND FilingOctober 23rd, 2018
TGen-Led Study of Metastatic Melanoma Secures $2 Million GrantAugust 29th, 2018
Join now to see all

Grant Support

Early Clinical Trials Of New Anti-Cancer AgentsNational Cancer Institute2008–2012
Correlative Studies For NCI Study#7916: Phase I Clinical Trial Of Intravenous FAUNational Cancer Institute2009–2010
Correlative Studies For NCI Study #7977: Phase I Trial Of ABT-888 PLUS IrinotecanNational Cancer Institute2008–2009
Phase I Clinical Trials Of New Anticancer AgentsNational Cancer Institute2003–2007
Foreign Accrual For U01ca62487 2006 Load Phase I U01National Cancer Institute2006
Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2002
Phase I Trials Of New Anticancer AgentsNational Cancer Institute1996–1997
New Drug Combinations For Breast CancerNational Cancer Institute1995–1996